ABSORB II, trial summary

A randomised clinical trial investigating the effect of (Absorb, Abbott Vascular, versus everolimus-eluting metallic stent in patients aged 18-85 years with evidence of myocardial ischaemia and one or two de-novo native lesions in different epicardial vessels

        Z

NCT01425281      



Studied treatment everolimus-eluting bioresorbable scaffold (Absorb, Abbott Vascular)
Control treatment everolimus-eluting metallic stent (Xience, Abbott Vascular)



Patients patients aged 18-85 years with evidence of myocardial ischaemia and one or two de-novo native lesions in different epicardial vessels
Group sizes335 / 166



Blindness single blind Inclusion period
Follow-up duration 1 year analysis Centers multicenter
Lost to FU geographical localisation
Primary endpoint Design Parallel groups



EndpointX1N1X0N0TE95% CI0,22,01,0

Serruys PW, Chevalier B, Dudek D, Cequier A, CarriĆ© D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015 Jan 3;385:43-54     [PMID: 25230593]   link to pdf   add to Mendeley  

    [PMID: ]   link to pdf   add to Mendeley  

Links

The Heart

The Heart

ClinicalTrial.gov record NCT01425281



Registering number NCT01425281 (see trial on clinicaltrials.gov)
Code Name

 

Appears in following systematic reviews: